Revolution Medicines shares promising data around KRAS drug combination
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Revolution Medicines shares promising data around KRAS drug combination" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Oncodaily, Medscape, Yahoo Finance and WSAW. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 49d ago.
Quick answers
Why is "Revolution Medicines shares promising data around KRAS drug combination" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 52d ago
- Practice-Changing Data in GI Oncology Medscape · 52d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 52d ago
- Experimental cancer drug brings time and hope for patients WSAW · 52d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 52d ago
Topics
Related trends
How Brentford FC’s Data Revolution Turned the Premier League Upside Down
5 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
Patients receive ‘historic’ pill for deadly pancreatic cancer
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
A mutant KRAS vaccine yields early positive results in its first human clinical trial for high-risk pancreatic cancer patients.
Overvalued, Bubble, or Revolution?
Financial markets focus intensely on the Magnificent Seven stocks amid widespread debate over valuation, bubble risks, and market concentration.
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
A Johns Hopkins-developed KRAS vaccine has demonstrated safety and durable immune responses in a trial focused on preventing pancreatic cancer in high-risk individuals.